CD274 and non-small cell lung carcinoma: In the Cityscape trial, the combination of tiragolumab (an anti TIGIT Ab) + atezolizumab vs. atezolizumab in PD-L1 positive, recurrent, or metastatic NSCLC, in first-line treatment, obtained a response rate of 31% vs. 16%, m PFS of 5.4 months vs. 3.6 months, HR 0.57, p = 0.015 [75].